|
Published by: Key Note Publications Ltd
Published: May. 1, 2008 - 134 Pages
Table of Contents
- Executive Summary
- 1. Market Definition
- REPORT COVERAGE
- Pharmacy-Only Medicines
- General Sales List Medicines
- MARKET SECTORS
- Analgesics (Pain Relief Medication)
- Skincare Treatments
- Cough, Cold and Sore Throat Remedies
- Gastrointestinal Remedies
- Other OTC Products
- MARKET TRENDS
- An Industry Dominated by the NHS
- Promotion of Self-Care
- An Expansion in Pharmacy Provision
- Extending the Role of Community Pharmacies
- Improving Access to Non-Prescription Medicines
- Product Development
- An Increasingly Consolidated Industry
- Household Expenditure
- Table 1: Average Weekly Household Expenditure on Health (£), 2004/2005 and 2006/2007
- Figure 1: Average Weekly Household Expenditure on Health (£), 2004/2005 and 2006/2007
- ECONOMIC TRENDS
- Population
- Table 2: UK Resident Population Estimates by Sex (000), Mid-Years 2003-2007
- Table 3: UK Resident Population Estimates and Projections (000 and %), Mid-Years 2002, 2006, 2011, 2016 and 2021
- Figure 2: UK Resident Population Estimates and Projections (%), Mid-Years 2002, 2006, 2011, 2016 and 2021
- Gross Domestic Product
- Table 4: UK Gross Domestic Product at Current and Annual Chain-Linked Prices (£m), 2003-2007
- Inflation
- Table 5: UK Rate of Inflation (%), 2003-2007
- Unemployment
- Table 6: Actual Number of Unemployed Persons in the UK (million), 2003-2007
- Household Disposable Income
- Table 7: UK Household Disposable Income Per Capita (£), 2003-2007
- MARKET POSITION
- The UK
- Table 8: The Total UK Pharmaceutical Market by Value (£m at rsp), 2003-2007
- Figure 3: The Total UK Pharmaceutical Market by Value (£m at rsp), 2003-2007
- Table 9: Leading Ten Pharmaceutical/Biotechnology Companies by Expenditure in Research and Development in the UK (£m and %), 2006/2007
- Overseas
- Table 10: Annual Average Medicine Usage Per Person in Selected Countries (£), 2004
- Table 11: Expenditure on Medicines as a Percentage of Gross Domestic Product in Selected Countries (%), 2004
- 2. Market Size
- THE TOTAL MARKET
- Table 12: The Total Over-the-Counter Pharmaceuticals Market in Great Britain by Value (£m at rsp), 2003-2007
- Figure 4: The Total Over-the-Counter Pharmaceuticals Market in Great Britain by Value (£m at rsp), 2003-2007
- BY MARKET SECTOR
- Figure 5: The Estimated Total Over-the-Counter Pharmaceuticals Market in Great Britain by Sector by Value (%), 2007
- Analgesics
- Table 13: The Analgesics Sector in Great Britain by Subsector by Value (£m at rsp), 2003-2007
- Skincare Treatments
- Table 14: The Skincare Treatments Sector in Great Britain by Subsector by Value (£m at rsp), 2003-2007
- Cough, Cold and Sore Throat Remedies
- Table 15: The Cough, Cold and Sore Throat Remedies Sector in Great Britain by Subsector by Value (£m at rsp), 2003-2007
- Gastrointestinal Remedies
- Table 16: The Gastrointestinal Remedies Sector in Great Britain by Subsector by Value (£m at rsp), 2003-2007
- Other OTC Products
- Table 17: The Other Over-the-Counter Products Sector in Great Britain by Subsector by Value (£m at rsp), 2003-2007
- OVERSEAS TRADE
- Table 18: UK Trade in Pharmaceuticals (£m), 2003-2007
- Figure 6: UK Trade in Pharmaceuticals (£m), 2003-2007
- 3. Industry Background
- RECENT HISTORY
- The Pharmaceutical Market
- The OTC Pharmaceutical Market
- NUMBER OF COMPANIES
- EMPLOYMENT
- REGIONAL VARIATIONS IN THE MARKETPLACE
- DISTRIBUTION
- Pharmacies
- Table 19: The Number of NHS-Contracted Community Pharmacies in England and Wales, 2002/2003 to 2006/2007
- Figure 7: The Number of NHS-Contracted Community Pharmacies in England and Wales, 2002/2003 to 2006/2007
- Retailers
- Table 20: Retail Distribution of Pharmacies by Consumer Usage (%), 2005
- Wholesalers
- Full-Line Wholesalers
- Short-Line Wholesalers
- Specialist Distributors (Parallel Traders)
- Self-Distributors
- Direct Distribution, Mail Order and Online Trading
- HOW ROBUST IS THE MARKET?
- LEGISLATION
- Medicines and Healthcare Products Regulatory Agency
- Better Regulation of Over-the-Counter Medicines Initiative
- KEY TRADE ASSOCIATIONS
- Association of the British Pharmaceutical Industry
- Association of the European Self-Medication Industry
- British Association of Pharmaceutical Wholesalers
- European Association of Pharmaceutical Full-Line Wholesalers
- Proprietary Association of Great Britain
- 4. Competitor Analysis
- THE MARKETPLACE
- Introduction
- The OTC Pharmaceuticals Market
- MARKET LEADERS
- Bayer HealthCare
- Company Structure
- Current and Future Developments
- Financial Results
- GlaxoSmithKline PLC
- Company Structure
- Current and Future Developments
- Table 21: Top Five Consumer Healthcare Products for GlaxoSmithKline by Turnover (£m), Year Ending 31st December 2007
- Financial Results
- Johnson & Johnson
- Company Structure
- Current and Future Developments
- Financial Results
- Novartis UK Ltd
- Company Structure
- Current and Future Developments
- Financial Results
- Reckitt Benckiser PLC
- Company Structure
- Current and Future Developments
- Financial Results
- Wyeth
- Company Structure
- Current and Future Developments
- Financial Results
- OUTSIDE SUPPLIERS
- MARKETING ACTIVITY
- Main Media Advertising Expenditure
- Table 22: Main Media Advertising Expenditure on Over-the-Counter Pharmaceuticals by Main Therapeutic Area and Selected Brand (£000), Years Ending December 2006 and 2007
- Exhibitions and Trade Shows
- 5. Strengths, Weaknesses, Opportunities and Threats
- STRENGTHS
- WEAKNESSES
- OPPORTUNITIES
- THREATS
- 6. Buying Behaviour
- INTRODUCTION
- Key Findings
- Table 23: Consumer Attitudes Towards Over-the-Counter Pharmaceuticals (% of respondents), 2007 and 2008
- ATTITUDES TOWARDS OTC PHARMACEUTICALS
- Purchasing OTC Products
- Table 24: Attitudes Towards Purchasing Over-the-Counter Products (% of respondents), 2008
- Taking OTC Products as a Preventative Measure
- Table 25: Attitudes Towards Taking Over-the-Counter Products as a Preventative Measure (% of respondents), 2008
- Availability of OTC Products and Concern Over Side Effects
- Table 26: Attitudes Towards the Availability of Over-the-Counter Products and Concern Over Side Effects (% of respondents), 2008
- Asking a Pharmacist for Advice About OTC Products
- Table 27: Attitudes Towards Asking a Pharmacist for Advice About OTC Products (% of respondents), 2008
- GP Recommendations of OTC Medicines
- Table 28: General Practitioner Recommendations of Over-the-Counter Medicines (% of respondents), 2007
- Self-Medication Based on Cost Issues
- Table 29: Self-Medication Based on Cost Issues (% of respondents), 2007
- Use of OTC Medicines Based on Convenience
- Table 30: Use of Over-the-Counter Medicines Based on Convenience (% of respondents), 2007
- Effectiveness of OTC Medicines Compared With Alternative Medicines
- Table 31: Effectiveness of OTC Medicines Compared With Alternative Medicines (% of respondents), 2007
- USAGE OF OTC PHARMACEUTICALS
- Usage of Over-the-Counter Pharmaceuticals
- Table 32: Use of Selected Over-the-Counter Pharmaceuticals in the Last 12 Months by Sex (% of adults), 2007
- COMMON MEDICAL CONDITIONS
- Table 33: Penetration of Selected Common Medical Conditions in the Last 12 Months by Sex and Age (% of adults), 2007
- SOURCES OF MEDICAL ADVICE
- Table 34: Sources Consulted for Medical Advice in the Last 12 Months by Sex and Age (% of adults), 2007
- SOURCES OF MEDICINES
- Table 35: Sources of Medicine Used in the Last 12 Months by Sex and Age (% of adults), 2007
- 7. Current Issues
- THE WIDENING USAGE OF OTC MEDICINES
- THE WIDENING USAGE OF SELF-CARE
- THE ROLE OF PHARMACISTS
- THE ROLE OF GENERAL PRACTITIONERS
- TARGETING OBESITY
- 8. The Global Market
- THE EUROPEAN MARKET
- Table 36: The European Non-Prescription Market by Selected Countries by Value (em and %), 2006
- KEY TRENDS
- The Widening of OTC Pharmaceuticals
- Medicine Status and Availability of OTC Products
- THE FUTURE
- Harmonisation
- 9. Forecasts
- INTRODUCTION
- The Economy
- Population
- Table 37: Forecast UK Resident Population by Sex (000), Mid-Years 2008-2012
- Gross Domestic Product
- Table 38: Forecast UK Growth in Gross Domestic Product in Real Terms (%), 2008-2012
- Inflation
- Table 39: Forecast UK Rate of Inflation (%), 2008-2012
- Unemployment
- Table 40: Forecast Actual Number of Unemployed Persons in the UK (million), 2008-2012
- FORECASTS 2008 TO 2012
- Table 41: The Forecast Total Over-the-Counter Pharmaceuticals Market in Great Britain by Value (£m at rsp), 2008-2012
- Figure 8: The Forecast Total Over-the-Counter Pharmaceuticals Market in Great Britain by Value (£m at rsp), 2008-2012
- Table 42: The Forecast Total Over-the-Counter Pharmaceuticals Market in Great Britain by Sector by Value (£m at rsp), 2008-2012
- MARKET GROWTH
- Figure 9: Growth in the Total Over-the-Counter Pharmaceuticals Market in Great Britain by Value (£m at rsp), 2003-2012
- FUTURE TRENDS
- Good Health for Ageing Baby Boomers
- The Self-Care Context
- A State-Supported System for Medicine
- 10. Company Profiles
- Bayer PLC
- Glaxosmithkline Plc
- Johnson & Johnson Ltd
- Novartis Uk Ltd
- Reckitt Benckiser Plc
- 11. Further Sources
- Associations
- Publications
- General Sources
- Government Publications
- Other Sources
- Bisnode Sources
AbstractThe market for over-the-counter (OTC) pharmaceuticals resides within a healthcare market that is largely free at the point of delivery for the majority of patients. Around 87% of prescriptions are dispensed free of charge — even medicines for minor complaints such as coughs and colds can be obtained in this way. Medicines that are deemed safe enough, and are in sufficiently controlled dosages, can be released from prescription-only medicine (POM) status and sold to consumers either under the supervision of a pharmacist; through a pharmacy only (P) or in the wider retail market (on general sale; GSL), but this `switching' system is tightly controlled.
As such, there are strong constraints on what the OTC pharmaceuticals market can achieve in terms of stimulating consumer interest in new products and increasing uptake. However, for consumers who are not exempt from the prescription charge, OTC medicines offer an attractive and often cheaper alternative than going to the doctor; the industry is keen to target this core consumer group of young and middle-aged working adults.
Performance in the market has been slow over the review period: Key Note estimates that, between 2003 and 2007, the market for OTC pharmaceuticals grew by 6.3%, to £2.13bn. Fierce retail competition among the pharmacy multiples, and price wars stimulated by grocery multiples that are keen to increase share in this sector, have eroded value growth. Where there has been sector growth, it has largely been in so-called `lifestyle' products, such as smoking deterrents and skin creams, as well as vitamins, minerals and supplements (VMS).
The Government is keen to widen the scope for self-care and the self-management of illness within the health service. However, moves to increase the role of pharmacies and pharmacists in treating minor conditions, and to free up general practitioners (GPs), have so far lacked any real, established national cohesion. The number of NHS-contracted community pharmacies has increased since 2005/2006, reversing a trend of decline from 2000, and there are signs that the Government is committed to giving increased emphasis to self-care, albeit slowly.
Despite the low growth rates in the overall market, OTC brands of popular products are a strong target for pharmaceutical companies looking to strengthen sales. Margins are usually high for OTC pharmaceuticals, since the cost of generic production is low. Brand loyalty is also high for popular brands, such as Nurofen, Anadin and Gaviscon. Two major mergers in 2006 — between Johnson & Johnson and Pfizer's consumer division, and between Reckitt Benckiser and Boots Healthcare International — underlined the fact that, although currently flat, this market is a robust and reliable one for investors.
Although future growth rates are forecast to be flat — with Key Note forecasting year-on-year increases of between 0.8% and 1.8% to 2012 — this is in no way a declining market. Some up-and-coming product development in areas such as obesity, points the way for future expansion.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
